Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis

• Published in: Lipids in health and disease 2017-12, Vol.16 (1), p.228-228, Article 228
• Main Authors: Du, Shui-Xian, Lu, Lin-Lin, Geng, Ning, Victor, David W, Chen, Li-Zhen, Wang, Cong, Yue, Hai-Yan, Xin, Yong-Ning, Xuan, Shi-Ying, Jin, Wen-Wen
• Format: Article
• Language: English
• Subjects: Alcohol use; Bias; Care and treatment; Clinical trials; Fatty liver; Ferritin; Hepatology; Insulin resistance; Liver diseases; Meta-analysis; Metabolism; NMR; Non-alcoholic fatty liver (NAFL); Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Nuclear magnetic resonance; Researchers; Risk factors; Serum ferritin (SFL); Studies
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-017-0613-4

A growing number of studies reported the connection between the level of serum ferritin (SFL) and non-alcoholic fatty liver disease (NAFLD). However, such connection was still disputable. The aim of our meta-analysis was to estimate SFL between the groups as below: patients with NAFLD against control group; non-alcoholic steatohepatitis (NASH) patients against control group; non-alcoholic fatty liver (NAFL) patients against a control group and NASH patients vs NAFL patients. We screened the studies in PubMed, EMBASE, the Cochrane Database and the Cochrane Central register controlled trials from the beginning to July 10, 2016 to find the studies indicated the connection between SFL and NAFLD (NAFL and/or NASH). Fourteen published studies which evaluate the SFL in NAFLD patients were selected. Higher SFL was noticed in NAFLD patients against control group (standardized mean difference [SMD] 1.01; 95% CI 0.89, 1.13), NASH patients against control group (SMD 1.21; 95% CI 1.00, 1.42), NAFL patients against control group (SMD 0.51; 95% CI 0.24, 0.79) and NASH patients against NAFL patients (SMD 0.63; 95% CI 0.52, 0.75). These results remained unaltered actually after the elimination of studies which were focused on paediatric or adolescent populations. Higher SFL was presented in NAFLD patients against the control group (SMD 1.08; 95% CI 0.95, 1.20) in adults and NASH patients against NAFL patients in adults (SMD 0.74; 95% CI 0.62, 0.87). The connection between SFL and NASH against NAFL group in paediatric or adolescent populations was observed inconsistently (SMD 0.10; 95% CI -0.18, 0.38). The level of SFL was elevated in patients with NAFLD (NAFL and/or NASH) compared with the controls. Compared with NAFL, The level of SFL was increased in NASH. The result remained unaltered actually after the elimination of studies focused on paediatric or adolescent populations.